Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Upstream Bio, Inc. (UPB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: UPB (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $56.5
1 Year Target Price $56.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 64.89% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 407.33M USD | Price to earnings Ratio - | 1Y Target Price 56.5 |
Price to earnings Ratio - | 1Y Target Price 56.5 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 5.14 - 29.46 | Updated Date 08/10/2025 |
52 Weeks Range 5.14 - 29.46 | Updated Date 08/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.36 |
Earnings Date
Report Date 2025-08-06 | When Before Market | Estimate -0.61 | Actual -0.74 |
Profitability
Profit Margin - | Operating Margin (TTM) -3112.52% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 188616167 | Price to Sales(TTM) 184.56 |
Enterprise Value 188616167 | Price to Sales(TTM) 184.56 | ||
Enterprise Value to Revenue 85.46 | Enterprise Value to EBITDA - | Shares Outstanding 53596600 | Shares Floating 28482306 |
Shares Outstanding 53596600 | Shares Floating 28482306 | ||
Percent Insiders 19.81 | Percent Institutions 85.58 |
Upturn AI SWOT
Upstream Bio, Inc.
Company Overview
History and Background
Upstream Bio, Inc. is a clinical-stage biopharmaceutical company founded in 2022. It focuses on developing novel therapies for inflammatory diseases. The company aims to address unmet needs in immunology by targeting key mediators of inflammation.
Core Business Areas
- Drug Development: Development of small molecule and biologic therapeutics for inflammatory diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
- Research and Discovery: Identifying and validating novel drug targets in immunology.
Leadership and Structure
Upstream Bio is led by CEO Adam Rogers. The company has a management team with expertise in drug development, immunology, and business operations. The organizational structure is focused on efficient execution of clinical programs and research initiatives.
Top Products and Market Share
Key Offerings
- UPB-101: UPB-101 is an IGLR1 antagonist being developed for the treatment of asthma and other inflammatory diseases. It is currently in Phase 1 clinical trials. Market share data is not yet available as the product is pre-revenue. Competitors include companies developing treatments for asthma, such as Amgen (AMGN) and Regeneron (REGN).
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing growth due to advances in drug development technologies and an aging population. The market for inflammatory disease therapeutics is substantial, driven by the high prevalence of conditions like asthma, rheumatoid arthritis, and inflammatory bowel disease.
Positioning
Upstream Bio is positioned as an innovator in the immunology space, focusing on novel targets and therapies. Its competitive advantage lies in its experienced management team and its focus on a validated drug target.
Total Addressable Market (TAM)
The TAM for inflammatory disease therapeutics is estimated to be over $100 billion. Upstream Bio is positioned to capture a portion of this market with its lead drug candidate, UPB-101. The actual portion depends on clinical trial success and future commercialization.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on novel drug targets
- Strong financial backing (Series A funding)
- Promising lead drug candidate (UPB-101)
Weaknesses
- Early-stage company with no marketed products
- High risk of clinical trial failure
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a single lead drug candidate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with additional drug candidates
- Positive clinical trial results for UPB-101
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
- Economic downturn impacting funding availability
Competitors and Market Share
Key Competitors
- AMGN
- REGN
- SNY
Competitive Landscape
Upstream Bio competes with established pharmaceutical companies in the inflammatory disease space. Its advantage lies in targeting IGLR1, offering potential first-in-class therapy. Its disadvantage is limited resources compared to larger companies.
Growth Trajectory and Initiatives
Historical Growth: The company is currently in its early stages, with growth focused on advancing UPB-101 through clinical trials.
Future Projections: Future growth is dependent on successful clinical trials and potential partnerships or acquisitions. Analyst estimates are not yet available.
Recent Initiatives: Focus on advancing UPB-101 into and through Phase 1 trials.
Summary
Upstream Bio is a clinical-stage biopharmaceutical company with a promising lead drug candidate targeting IGLR1. While the company is early in its development, its experienced management and strong financial backing position it well. The company needs to successfully execute its clinical trials to realize its potential and should consider potential acquisitions to expand its pipeline. It will also need to be able to compete with larger pharmaceutical companies with deeper pockets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Upstream Bio Press Releases
- Company Website
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and limited details. Market share and financial data are estimated where not explicitly reported. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Upstream Bio, Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2024-10-11 | CEO & Director Dr. E. Rand Sutherland M.D., M.P.H., MPH | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://upstreambio.com |
Full time employees 52 | Website https://upstreambio.com | ||
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.